Abstract 4834
Background
For extensive-stage small cell lung cancer (ES-SCLC) patients with progressive or recurrent disease after platinum-based combination chemotherapy, topotecan is recommended as second-line treatment. However, although some patients may achieve at least an objective response with topotecan, response duration is often short. Belotecan, a camptothecin derivative, inhibits topoisomerase I. Previous studies have demonstrated that belotecan has active antitumor activity against advanced SCLC and ovarian cancers. We report safety data from a phase IIb randomized multicenter study of belotecan as second-line treatment for progressive/recurrent limited-disease (LD)- or ES-SCLC.
Methods
This study, conducted from March 2010 to March 2018, was designed to prove the non-inferiority of belotecan to topotecan. Patients with recurrent ES-SCLC were randomized (1:1 ratio) to belotecan 0.5 mg/m2 or topotecan 1.5 mg/m2 intravenously for 5 consecutive days every 3 weeks for 6 cycles or until disease progression. Adverse events (AEs) were reported according to NCI-CTCAE (ver. 4.0) and categorized by System Organ Class and Preferred Term.
Results
Overall, 161 patients (belotecan, n = 80; topotecan, n = 81) were evaluable in the safety analysis set. Clinical characteristics were well balanced between the treatment arms. Although belotecan recipients received significantly more treatment cycles than topotecan recipients (p = 0.0210), there were no between-group differences in the number of patients who required dose reductions or who omitted treatment in each cycle. There were no statistically significant between-group differences in safety results: any AEs (including grade 3 or 4 AEs), adverse drug reactions (ADRs), severe AEs (SAEs) or severe ADRs (SADRs). The most common AEs in the belotecan and topotecan groups, respectively, were decreased neutrophil count (61 patients [76.3%] vs. 67 patients [82.7%]), anemia (37 [46.3% vs. 44 [54.3%]), decreased platelet count (33 [41.3%] vs. 43 [53.1%]), nausea (35 [43.8%] vs. 30 [37.0%), and anorexia (32 [40.0% vs. 36 [44.4%]).
Conclusions
Our study indicates that belotecan is a safe second-line treatment option for patients with progressive/recurrent LD- or ES-SCLC.
Clinical trial identification
NCT01497873.
Legal entity responsible for the study
Chong Kun Dang Pharmaceutical Corp.
Funding
Chong Kun Dang Pharmaceutical Corp.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract